Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546074 | 0.76 | XDH (0.35) | PDPK1 | |
| SCHEMBL442759 | 0.75 | PNP (0.32) | PDPK1PARP1 | |
| SCHEMBL9426162 | 0.75 | — | — | |
| SCHEMBL3444335 | 0.75 | CSNK2A1 (0.34) | PARP1 | |
| SCHEMBL8169178 | 0.75 | BCL2 (0.34) | — | |
| SCHEMBL545951 | 0.75 | PDPK1 (0.37) | PDPK1 | |
| SCHEMBL15421692 | 0.71 | — | — | |
| SCHEMBL129804 | 0.70 | PDPK1 (0.37) | PDPK1PARP1 | |
| SCHEMBL21393150 | 0.68 | PDPK1 (0.36) | PDPK1PARP1 | |
| SCHEMBL13505953 | 0.67 | HTT (0.41) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211713-A1 | Compounds having selective hydrolytic potentials | CELL THERAPEUTICS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-0739203-A4 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS INC (US) | 2000-12-20 | — | — | EP | claimed |
| US-5985926-A | VIRICIDES OF AMINE COMPOUNDS AND HYDROCARBONS | CELL THERAPEUTICS, INC. (US) | 1999-11-16 | — | — | US | claimed |
| US-5641783-A | ANTIINFLAMMATORY OR IMMUNOSUPPRESSIVE AGENTS | CELL THERAPEUTICS, INC. (US) | 1997-06-24 | — | — | US | claimed |
| EP-0739203-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1996-10-30 | — | — | EP | claimed |
| EP-0676958-A1 | METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION | CELL THERAPEUTICS, INC. (US) | 1995-10-18 | — | — | EP | claimed |
| WO-1995019171-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1995-07-20 | — | — | WO | claimed |
| WO-1995013808-A1 | METHOD FOR SELECTIVELY INHIBITING IL-2 SIGNAL TRANSDUCTION | CELL THERAPEUTICS, INC. (US) | 1995-05-26 | — | — | WO | claimed |
| WO-1995012396-A1 | METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION | CELL THERAPEUTICS, INC. (US) | 1995-05-11 | — | — | WO | claimed |
| WO-1994018192-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 1994-08-18 | — | — | WO | claimed |
| EP-3458488-A1 | PROCESS FOR PRODUCING FUNCTIONALIZED POLYMERS | Bridgestone Corporation (JP) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017201397-A1 | PROCESS FOR PRODUCING FUNCTIONALIZED POLYMERS | BRIDGESTONE CORPORATION (JP) | 2017-11-23 | — | — | WO | disclosed |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20090269313-A1 | ENCAPSULATION SYSTEM | DIAKINE THERAPEUTICS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009099582-A2 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-1995019171-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1995-07-20 | — | — | WO | disclosed |
| WO-1995013808-A1 | METHOD FOR SELECTIVELY INHIBITING IL-2 SIGNAL TRANSDUCTION | CELL THERAPEUTICS, INC. (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1995013075-A1 | METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA | CELL THERAPEUTICS, INC. (US) | 1995-05-18 | — | — | WO | disclosed |
| WO-1995012396-A1 | METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION | CELL THERAPEUTICS, INC. (US) | 1995-05-11 | — | — | WO | disclosed |
| WO-1994018192-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211713-A1 | Compounds having selective hydrolytic potentials | CTSS, CTSE, GAA | PDPK1 1867/4885PARP1 302/4885 |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | PDPK1 1238/4885PARP1 4107/4885 |
| US-20090269313-A1 | ENCAPSULATION SYSTEM | GPR119, IAPP, LIPA | PDPK1 3719/4885PARP1 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.